17-beta-hydroxysteroid dehydrogenase deficiency overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(18 intermediate revisions by 2 users not shown)
Line 5: Line 5:
{{SK}} 17-beta hydroxysteroid dehydrogenase III deficiency, 17-ketosteroid reductase deficiency of testis, 17-KSR deficiency, Neutral 17-beta-hydroxysteroid oxidoreductase deficiency, Male Pseudo hermaphroditism with gynecomastia, Testosterone 17-beta-dehydrogenase deficiency
{{SK}} 17-beta hydroxysteroid dehydrogenase III deficiency, 17-ketosteroid reductase deficiency of testis, 17-KSR deficiency, Neutral 17-beta-hydroxysteroid oxidoreductase deficiency, Male Pseudo hermaphroditism with gynecomastia, Testosterone 17-beta-dehydrogenase deficiency
==Overview==
==Overview==
'''17-beta-hydroxysteroid dehydrogenase deficiency''' is a rare [[autosomal]] [[recessive]] [[developmental]] [[disorder]] that affects male [[sexual]] [[development]].  Individuals with this condition are genetically male and have [[testes]], but do not produce enough [[testosterone]]. The synthesis of [[testosterones]] is impaired and the levels in the serum is low which disrupts the formation of [[external]] [[male]] [[genitalia]] before [[birth]]. The affected individual is male with [[XY]] [[chromosomes]] with [[phenotype]] [[female]] or [[ambiguous]] [[external]] [[genitalia]] which is the external genitalia do not look clearly male or clearly female , characterized by [[clitoromegaly]], [[posterior]] [[labioscrotal]] fusion and [[perineal]] [[blind]] [[vaginal]] [[pouch]]. [[Testes]] are located in [[inguinal]] or in the [[labioscrotal folds]]. The [[internal]] [[urogenital]] [[tract]] ([[epididymis]], [[vasa deferential]], [[seminal vesicles]], [[ejaculatory ducts]]) is well developed; [[prostate]] and [[Müllerian structures]] are absent. Majority of cases do not present until [[puberty]], at which time [[peripheral]] conversion of [[androgen]] [[precursors]] causes ongoing [[virilization]]. Although some patients with less severe defects are brought up as males, affected males are usually raised as girls. During puberty, the affected patients present with either [[primary amenorrhea]] or sudden onset of virilization and most of the affected individuals develop male [[secondary sex characteristics]], such as increased [[muscle mass]], [[deepening]] of the [[voice]], and development of [[male]] [[pattern]] body [[hair]]. [[HSD17B3]] gene [[mutations]] result in a 17-beta hydroxysteroid dehydrogenase 3 enzyme with decrease or no activity, reducing production of [[testosterone]] from [[androstenedione]]. [[Genetic]] [[analysis]] can confirm the [[diagnosis]]. [[Gonadectomy]] is recommended to prevent continuous [[virilization]] if a female [[gender]] [[identity]] is established. The risk of [[testicular]] [[neoplasia]] has not been determined, a point which should be discussed if patients choose to transition into a male gender role. All affected people with the disease are [[infertile]].
17-beta-hydroxysteroid dehydrogenase deficiency is a rare [[autosomal]] [[recessive]] [[developmental]] [[disorder]] that affects male [[sexual]] [[development]].  Individuals with this condition are genetically male and have [[testes]], but do not produce enough [[testosterone]]. The synthesis of [[testosterones]] is impaired and the levels in the serum is low which disrupts the formation of [[external]] [[male]] [[genitalia]] before [[birth]]. The affected individual is male with [[XY]] [[chromosomes]] with [[phenotype]] [[female]] or [[ambiguous]] [[external]] [[genitalia]] which is the external genitalia do not look clearly male or clearly female , characterized by [[clitoromegaly]], [[posterior]] [[labioscrotal]] fusion and [[perineal]] [[blind]] [[vaginal]] [[pouch]]. [[Testes]] are located in [[inguinal]] or in the [[labioscrotal folds]]. The [[internal]] [[urogenital]] [[tract]] ([[epididymis]], [[vasa deferential]], [[seminal vesicles]], [[ejaculatory ducts]]) is well developed; [[prostate]] and [[Müllerian structures]] are absent. Majority of cases do not present until [[puberty]], at which time [[peripheral]] conversion of [[androgen]] [[precursors]] causes ongoing [[virilization]]. Although some patients with less severe defects are brought up as males, affected males are usually raised as girls. During puberty, the affected patients present with either [[primary amenorrhea]] or sudden onset of virilization and most of the affected individuals develop male [[secondary sex characteristics]], such as increased [[muscle mass]], [[deepening]] of the [[voice]], and development of [[male]] [[pattern]] body [[hair]]. [[HSD17B3]] gene [[mutations]] result in a 17-beta hydroxysteroid dehydrogenase 3 enzyme with decrease or no activity, reducing production of [[testosterone]] from [[androstenedione]]. [[Genetic]] [[analysis]] can confirm the [[diagnosis]]. [[Gonadectomy]] is recommended to prevent continuous [[virilization]] if a female [[gender]] [[identity]] is established. The risk of [[testicular]] [[neoplasia]] has not been determined, a point which should be discussed if patients choose to transition into a male gender role. All affected people with the disease are [[infertile]].


==Historical Perspectives==
==Historical Perspectives==
17 beta hydroxysteroid dehydrogenase III deficiency is initially described in 1971 by Saez and his [[colleagues]].
17 beta hydroxysteroid dehydrogenase III deficiency was initially described in 1971 by Saez and his [[colleagues]].


==Classification==
==Classification==
No sufficient data for [[classification]] of 17 beta hydroxysteroid dehydrogenase deficiency.
There is no [[classification]] of 17 beta hydroxysteroid dehydrogenase deficiency.


==Pathophysiology==
==Pathophysiology==
17-beta-hydroxysteroid dehydrogenase deficiency-3 is [[biochemically]] characterized by decreased levels of [[testosterone]] and increased levels of [[androstenedione]] as a result of the defect in conversion of [[androstenedione]] into [[testosterone]].
17-beta-hydroxysteroid dehydrogenase deficiency is [[biochemically]] characterized by decreased levels of [[testosterone]] and increased levels of [[androstenedione]] as a result of the defect in conversion of [[androstenedione]] into [[testosterone]].


==Causes==
==Causes==
HSD17B3 gene mutation causes 17-beta hydroxysteroid dehydrogenase deficiency results a decrease in [[testosterones]] production. The reduction of testosterones affects the development of male reproductive tract which results [[phenotypically]] female or [[ambiguous external genitalia]].
HSD17B3 gene mutation causes 17-beta hydroxysteroid dehydrogenase deficiency results a decrease in [[testosterone]] production. The reduction of testosterone affects the development of male reproductive tract which results [[phenotypically]] female or [[ambiguous external genitalia]].
 
==Differentiating 17 Beta hydroxysteroid Dehydrogenase Deficiency from Other Diseases==
==Differentiating 17 Beta hydroxysteroid Dehydrogenase Deficiency from Other Diseases==
17 beta hydroxysteroid dehydrogenase deficiency should be differentiated from other diseases that cause [[ambiguous genitalia]].
17-beta-hydroxysteroid dehydrogenase deficiency should be differentiated from other diseases that cause [[ambiguous genitalia]].
 
==Epidemiology and Demographics==
==Epidemiology and Demographics==
Although the precise [[incidence]] of 17βHSD-3 deficiency is unknown, a recent study from the [[Netherlands]] estimated the incidence around 1 in 147,000 [[newborns]], with a calculated [[heterozygote]] frequency of 1 in 135.
Although the precise [[incidence]] of 17βHSD-3 deficiency is unknown, a recent study from the [[Netherlands]] estimated the incidence around 1 in 147,000 [[newborns]], with a calculated [[heterozygote]] frequency of 1 in 135.
Line 25: Line 27:
The potential risk factor for the development of 17 beta hydroxysteroid dehydrogenase 3 deficiency is positive [[family history]].
The potential risk factor for the development of 17 beta hydroxysteroid dehydrogenase 3 deficiency is positive [[family history]].
==Screening==
==Screening==
There is insufficient evidence to recommend routine screening for 17 alpha-hydroxylase deficiency.
There is insufficient evidence to recommend routine screening for 17-beta-hydroxysteroid dehydrogenase deficiency.
 
==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
The characteristic phenotype at birth is an [[XY]] individual with female or [[ambiguous external genitalia]]. The majority of those affected have female [[external genitalia]] and consequently are raised as girls.
The characteristic phenotype at birth is an [[XY]] individual with female or [[ambiguous external genitalia]]. The majority of those affected have female [[external genitalia]] and consequently are raised as girls.
==Diagnosis==
==Diagnosis==
===History and Symptoms===
===History and Symptoms===
17-beta-hydroxysteroid dehydrogenase deficiency-3 is clinically characterized by either [[ambiguous external genitalia]] or complete female external genitalia at birth; As a consequence of impaired male [[sexual differentiation]] in 46 XY individuals.
17-beta-hydroxysteroid dehydrogenase deficiency is clinically characterized by either [[ambiguous external genitalia]] or complete female external genitalia at birth; As a consequence of impaired male [[sexual differentiation]] in 46 XY individuals.
 
===Physical Examination===
===Physical Examination===
Majority of affected [[babies]] with 17-beta hydroxysteroid dehydrogenase 3 deficiency are born with [[external genitalia]] that appear female.
Majority of affected [[babies]] with 17-beta hydroxysteroid dehydrogenase 3 deficiency are born with [[external genitalia]] that appear female.
Line 36: Line 40:
Increased serum [[androstenedione]] and decreased serum testosterone/androstenedione ratios after hCG stimulation. The definitive diagnosis can be made from [[Genetic testing]].
Increased serum [[androstenedione]] and decreased serum testosterone/androstenedione ratios after hCG stimulation. The definitive diagnosis can be made from [[Genetic testing]].
===Molecular Genetic Studies===
===Molecular Genetic Studies===
17 beta hydroxysteroid dehydrogenase deficiency is inherited in an [[autosomal recessive]] pattern.
17-beta-hydroxysteroid dehydrogenase deficiency is inherited in an [[autosomal recessive]] pattern.
 
===Genotyping===
===Genotyping===
17 beta hydroxysteroid dehydrogenase deficiency is a condition with [[genotypically]] male and [[phenotypically]] female characteristics. There has been no phenotype to genotype correlation.
17-beta-hydroxysteroid dehydrogenase deficiency is a condition with [[genotypically]] male and [[phenotypically]] female or ambiguous genitalia characteristics. There has been no phenotype to genotype correlation.
===Pelvic X ray===
 
There are no pelvic x ray finding associated with 17 beta hydroxysteroid dehydrogenase 3 deficiency.
===X ray===
There are no [[x-ray]] findings associated with 17-beta-hydroxysteroid dehydrogenase deficiency.
 
===CT===
===CT===
There are no CT scan finding associated with 17 beta hydroxysteroid dehydrogenase 3 deficiency.
There are no CT scan findings associated with 17-beta-hydroxysteroid dehydrogenase deficiency.
 
===Ultrasound===
===Ultrasound===
Ultrasound of abdomen and pelvis showed absence of [[uterus]] or [[vagina]].
Ultrasound of abdomen and pelvis showed absence of [[uterus]] or [[vagina]].
Line 51: Line 59:
==Treatment==
==Treatment==
===Medical Therapy===
===Medical Therapy===
If the diagnosis of 17 beta hydroxysteroid dehydrogenase deficiency is made at birth, [[gender]] assignment should be discussed, depending on the expected result of [[virilization]] [[genioplasty]].
If the diagnosis of 17-beta-hydroxysteroid dehydrogenase deficiency is made at birth, [[gender assignment]] should be discussed, depending on the expected result of [[virilization]] [[genioplasty]]. Affected individuals who raised as male may [[virilize]] on their own or with the help of [[testosterone]] [[treatment]]. In female patients who underwent [[gonadectomy]], appropriate intervention with [[estrogen]] therapy should be introduced at the time of puberty to induce [[secondary sexual characteristics]].
 
===Surgical Therapy===
17-beta-hydroxysteroid dehydrogenase deficiency has a 28 % risk of [[germ cell tumor]] in [[disorder of sexual development]]. Consequently, close  monitoring is warranted for an individual who is raised as a male rather than removing the [[gonads]] at the time of diagnosis.
 
===Primary Prevention===
===Primary Prevention===
There is no known method to prevent 17 beta hydroxysteroid dehydrogenase deficiency.
There is no known method to prevent 17 beta hydroxysteroid dehydrogenase deficiency.
Line 64: Line 76:
[[Category:Endocrinology]]
[[Category:Endocrinology]]
[[Category:Genetic disorders]]
[[Category:Genetic disorders]]
[[Category:needs english review]]

Latest revision as of 07:43, 20 October 2022

17-beta-hydroxysteroid dehydrogenase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Molecular Genetic Studies

Genotyping

X Ray

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

17-beta-hydroxysteroid dehydrogenase deficiency overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 17-beta-hydroxysteroid dehydrogenase deficiency overview

CDC on 17-beta-hydroxysteroid dehydrogenase deficiency overview

17-beta-hydroxysteroid dehydrogenase deficiency overview in the news

Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency overview

Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency

Risk calculators and risk factors for 17-beta-hydroxysteroid dehydrogenase deficiency overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]

Synonyms and keywords: 17-beta hydroxysteroid dehydrogenase III deficiency, 17-ketosteroid reductase deficiency of testis, 17-KSR deficiency, Neutral 17-beta-hydroxysteroid oxidoreductase deficiency, Male Pseudo hermaphroditism with gynecomastia, Testosterone 17-beta-dehydrogenase deficiency

Overview

17-beta-hydroxysteroid dehydrogenase deficiency is a rare autosomal recessive developmental disorder that affects male sexual development. Individuals with this condition are genetically male and have testes, but do not produce enough testosterone. The synthesis of testosterones is impaired and the levels in the serum is low which disrupts the formation of external male genitalia before birth. The affected individual is male with XY chromosomes with phenotype female or ambiguous external genitalia which is the external genitalia do not look clearly male or clearly female , characterized by clitoromegaly, posterior labioscrotal fusion and perineal blind vaginal pouch. Testes are located in inguinal or in the labioscrotal folds. The internal urogenital tract (epididymis, vasa deferential, seminal vesicles, ejaculatory ducts) is well developed; prostate and Müllerian structures are absent. Majority of cases do not present until puberty, at which time peripheral conversion of androgen precursors causes ongoing virilization. Although some patients with less severe defects are brought up as males, affected males are usually raised as girls. During puberty, the affected patients present with either primary amenorrhea or sudden onset of virilization and most of the affected individuals develop male secondary sex characteristics, such as increased muscle mass, deepening of the voice, and development of male pattern body hair. HSD17B3 gene mutations result in a 17-beta hydroxysteroid dehydrogenase 3 enzyme with decrease or no activity, reducing production of testosterone from androstenedione. Genetic analysis can confirm the diagnosis. Gonadectomy is recommended to prevent continuous virilization if a female gender identity is established. The risk of testicular neoplasia has not been determined, a point which should be discussed if patients choose to transition into a male gender role. All affected people with the disease are infertile.

Historical Perspectives

17 beta hydroxysteroid dehydrogenase III deficiency was initially described in 1971 by Saez and his colleagues.

Classification

There is no classification of 17 beta hydroxysteroid dehydrogenase deficiency.

Pathophysiology

17-beta-hydroxysteroid dehydrogenase deficiency is biochemically characterized by decreased levels of testosterone and increased levels of androstenedione as a result of the defect in conversion of androstenedione into testosterone.

Causes

HSD17B3 gene mutation causes 17-beta hydroxysteroid dehydrogenase deficiency results a decrease in testosterone production. The reduction of testosterone affects the development of male reproductive tract which results phenotypically female or ambiguous external genitalia.

Differentiating 17 Beta hydroxysteroid Dehydrogenase Deficiency from Other Diseases

17-beta-hydroxysteroid dehydrogenase deficiency should be differentiated from other diseases that cause ambiguous genitalia.

Epidemiology and Demographics

Although the precise incidence of 17βHSD-3 deficiency is unknown, a recent study from the Netherlands estimated the incidence around 1 in 147,000 newborns, with a calculated heterozygote frequency of 1 in 135.

Risk Factors

The potential risk factor for the development of 17 beta hydroxysteroid dehydrogenase 3 deficiency is positive family history.

Screening

There is insufficient evidence to recommend routine screening for 17-beta-hydroxysteroid dehydrogenase deficiency.

Natural History, Complications, and Prognosis

The characteristic phenotype at birth is an XY individual with female or ambiguous external genitalia. The majority of those affected have female external genitalia and consequently are raised as girls.

Diagnosis

History and Symptoms

17-beta-hydroxysteroid dehydrogenase deficiency is clinically characterized by either ambiguous external genitalia or complete female external genitalia at birth; As a consequence of impaired male sexual differentiation in 46 XY individuals.

Physical Examination

Majority of affected babies with 17-beta hydroxysteroid dehydrogenase 3 deficiency are born with external genitalia that appear female.

Laboratory Findings

Increased serum androstenedione and decreased serum testosterone/androstenedione ratios after hCG stimulation. The definitive diagnosis can be made from Genetic testing.

Molecular Genetic Studies

17-beta-hydroxysteroid dehydrogenase deficiency is inherited in an autosomal recessive pattern.

Genotyping

17-beta-hydroxysteroid dehydrogenase deficiency is a condition with genotypically male and phenotypically female or ambiguous genitalia characteristics. There has been no phenotype to genotype correlation.

X ray

There are no x-ray findings associated with 17-beta-hydroxysteroid dehydrogenase deficiency.

CT

There are no CT scan findings associated with 17-beta-hydroxysteroid dehydrogenase deficiency.

Ultrasound

Ultrasound of abdomen and pelvis showed absence of uterus or vagina.

Other Imaging Findings

MRI of the abdomen and pelvis revealed absence of the uterus or vagina with likely gonadal tissue in the inguinal canals bilaterally with a cyst having a single sac contiguous to the gonadal tissue on the right

Other Diagnostic Studies

There is no other diagnostic studies found.

Treatment

Medical Therapy

If the diagnosis of 17-beta-hydroxysteroid dehydrogenase deficiency is made at birth, gender assignment should be discussed, depending on the expected result of virilization genioplasty. Affected individuals who raised as male may virilize on their own or with the help of testosterone treatment. In female patients who underwent gonadectomy, appropriate intervention with estrogen therapy should be introduced at the time of puberty to induce secondary sexual characteristics.

Surgical Therapy

17-beta-hydroxysteroid dehydrogenase deficiency has a 28 % risk of germ cell tumor in disorder of sexual development. Consequently, close monitoring is warranted for an individual who is raised as a male rather than removing the gonads at the time of diagnosis.

Primary Prevention

There is no known method to prevent 17 beta hydroxysteroid dehydrogenase deficiency.

Secondary Prevention

There is no known method to prevent 17 beta hydroxysteroid dehydrogenase deficiency.

References

Template:WH Template:WS